Netherlands· NL-fbba84940218

Ferriprox, 500 mg filmomhulde tabletten

A deferiprone product containing deferipron, registered in Netherlands by Chiesi Farmaceutici S.p.A.. The same ATC class is registered in 16 of our 19 countries.

ATC V03AC02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about deferipronAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Deferiprone is registered in 16 of 19 countries.

Countries holding a registration under ATC V03AC02 (deferiprone), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search deferiprone products by name

Deferiprone · ATC V03AC02

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deferiprone costs, country by country.

Normalised to the WHO defined daily dose (5.25 g), the median price runs from $22.61 in Switzerland to $8636.08 in Italy — a ×382 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Deferiprone · price per daily dose (5.25 g)

USD · FX 28 Sept 2026

IT Italy$8636.08
CH Switzerland$22.61

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: DEFERIPRON
Manufacturer: Chiesi Farmaceutici S.p.A.
Country: Netherlands (NL)
ATC code: V03AC02
ATC class: Deferiprone
Defined daily dose: 5.25 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/99/108

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

315 interactions on record for deferiprone.

Graded by severity as the source publishes them — 266 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check deferiprone against other medicines How interaction checks work

Deferiprone · interactions on record

315 records

266 severe
49 moderate

Most severe, free to view

FostamatinibB02BX09severe
ProcainamideC01BA02severe
TocainideC01BB03severe
PropylthiouracilH03BA02severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deferiprone in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deferiprone products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

Cyprus · Deferiprone Sapiens
Denmark · Deferipron Orifarm
France · Deferiprone Arrow
United Kingdom (Northern Ireland) · Deferiprone Mercury Pharmaceuticals, Deferiprone Mercury Pharmaceuticals Ltd.
Greece · Befeprox
Iceland · Ferriprox
Italy · Deferiprone Doc
Liechtenstein · Ferriprox
Norway · Ferriprox
Portugal · Befeprox, Deferriprona Generis
Sweden · Deferipron Evolan, Deferiprone Doc

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/0c5f4bee-308f-4701-993e-a426f10a8e23
GET /v1/drugs/0c5f4bee-308f-4701-993e-a426f10a8e23?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ferriprox-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Deferiprone",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp70430",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE (E 464)",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "DEFERIPRON"
  ],
  "leaflet_url": null,
  "authorised_at": "1999/08/25",
  "procedure_number": "EMEA/H/C/000236",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/99/108",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about deferiprone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console